Article
Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Jun 2011
Wu Jenn-Yu, Yu Chong-Jen, Chang Yeun-Chung, Yang Chih-Hsin, Shih Jin-Yuan, Yang Pan-Chyr
Abstract excerpt
PURPOSE: Clinical features of epidermal growth factor receptor (EGFR) mutations, L858R, deletions in exon 19, T790M, and insertions in exon 20, in non-small cell lung cancer (NSCLC) are well known. The clinical significance of other uncommon EGFR mutations, such as their association with the effectiveness of EGFR tyrosine kinase inhibitors (TKI), is not well understood. This study aimed to improve the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.